Kylie M. Wagstaff

Dr. Kylie M. Wagstaff


Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2020 in Antiviral Research
Verified
Journal Article
Open access
LCLeon Caly
Leon Caly
JDJulian D. Druce
Julian D. Druce
MCMike G. Catton
Mike G. Catton
DJDavid A. Jans
David A. Jans
KWKylie M. Wagstaff
Kylie M. Wagstaff
Although several clinical trials are now underway to test possible therapies, the worldwide response to the COVID-19 outbreak has been largely limited to monitoring/containment. We report here that Ivermectin, an FDA-approved anti-parasitic previously shown to have broad-spectrum anti-viral activity in vitro, is an inhibitor of the causative virus (SARS-CoV-2), with a single addition to Vero-hSLAM cells 2 h post infection with SARS-CoV-2 able to effect ~5000-fold reduction in viral RNA at 48 h. Ivermectin therefore warrants further investigation for possible benefits in humans.

16 April 2012 in Biochemical Journal
Verified
Journal Article
Open access
PDF file
KWKylie M. Wagstaff
Kylie M. Wagstaff
HSHaran Sivakumaran
Haran Sivakumaran
SHSteven H
Steven H
DHDavid Harrich
David Harrich
DJDavid Jans
David Jans
The movement of proteins between the cytoplasm and nucleus mediated by the importin superfamily of proteins is essential to many cellular processes, including differentiation and development, and is critical to disease states such as viral disease and oncogenesis. We recently developed a high-throughput screen to identify specific and general inhibitors of protein nuclear import, from which ivermectin was identified as a potential inhibitor of importin α/β-mediated transport. In the present study, we characterized in detail the nuclear transport inhibitory properties of ivermectin, demonstrating that it is a broad-spectrum inhibitor of importin α/β nuclear import, with no effect on a range of other nuclear import pathways, including that mediated by importin β1 alone. Importantly, we establish for the first time that ivermectin has potent antiviral activity towards both HIV-1 and dengue virus, both of which are strongly reliant on importin α/β nuclear import, with respect to the HIV-1 integrase and NS5 (non-structural protein 5) polymerase proteins respectively. Ivermectin would appear to be an invaluable tool for the study of protein nuclear import, as well as the basis for future development of antiviral agents.

13 May 2010 in PLOS Pathogens
Verified
Journal Article
Open access
PDF file
HNHayley J. Newton
Hayley J. Newton
JPJaclyn S. Pearson
Jaclyn S. Pearson
LBLuminita Badea
Luminita Badea
MKMichelle Kelly
Michelle Kelly
MLMark Lucas
Mark Lucas
EHElizabeth Hartland
Elizabeth Hartland
Many bacterial pathogens utilize a type III secretion system to deliver multiple effector proteins into host cells. Here we found that the type III effectors, NleE from enteropathogenic E. coli (EPEC) and OspZ from Shigella, blocked translocation of the p65 subunit of the transcription factor, NF-κB, to the host cell nucleus. NF-κB inhibition by NleE was associated with decreased IL-8 expression in EPEC-infected intestinal epithelial cells. Ectopically expressed NleE also blocked nuclear translocation of p65 and c-Rel, but not p50 or STAT1/2. NleE homologues from other attaching and effacing pathogens as well OspZ from Shigella flexneri 6 and Shigella boydii, also inhibited NF-κB activation and p65 nuclear import; however, a truncated form of OspZ from S. flexneri 2a that carries a 36 amino acid deletion at the C-terminus had no inhibitory activity. We determined that the C-termini of NleE and full length OspZ were functionally interchangeable and identified a six amino acid motif, IDSY(M/I)K, that was important for both NleE- and OspZ-mediated inhibition of NF-κB activity. We also established that NleB, encoded directly upstream from NleE, suppressed NF-κB activation. Whereas NleE inhibited both TNFα and IL-1β stimulated p65 nuclear translocation and IκB degradation, NleB inhibited the TNFα pathway only. Neither NleE nor NleB inhibited AP-1 activation, suggesting that the modulatory activity of the effectors was specific for NF-κB signaling. Overall our data show that EPEC and Shigella have evolved similar T3SS-dependent means to manipulate host inflammatory pathways by interfering with the activation of selected host transcriptional regulators. Bacterial intestinal pathogens have evolved distinct ways of colonizing the gut and causing disease. Enteropathogenic E. coli (EPEC) and its close relative enterohemorrhagic E. coli O157:H7 (EHEC) are extracellular pathogens that cause a characteristic lesion on the intestinal mucosa known as an attaching and effacing lesion. In contrast, Shigella is an intracellular pathogen that invades the intestinal mucosa and spreads from cell to cell. Both pathogens utilize a bacterial type III secretion system that “injects” virulence effector proteins into the host cell upon contact. We have discovered that an effector shared by EPEC/EHEC and Shigella, known as NleE or OspZ, as well as another EPEC/EHEC effector, NleB, inhibit the host cell inflammatory response by preventing translocation of the immune regulator NF-κB to the cell nucleus. Thus, although EPEC/EHEC and Shigella have evolved different colonization strategies, they share a common virulence determinant that suppresses the inflammatory response of the host, and both pathogens mediate a multi-effector attack on NF-κB signaling.

10 August 2007 in Advanced Drug Delivery Reviews
Verified
Journal Article
Closed access
CPColin Pouton
Colin Pouton
KWKylie M. Wagstaff
Kylie M. Wagstaff
DRD Roth
D Roth
GMGregory Moseley
Gregory Moseley
DJDavid Jans
David Jans

1 February 2011 in SLAS Discovery
Verified
Journal Article
Open access
PDF file
KWKylie M. Wagstaff
Kylie M. Wagstaff
SRStephen M. Rawlinson
Stephen M. Rawlinson
AHAnna C. Hearps
Anna C. Hearps
DJDavid Jans
David Jans
Specific viral proteins enter the nucleus of infected cells to perform essential functions, as part of the viral life cycle. The integrase (IN) molecule of human immunodeficiency virus (HIV)–1 is of particular interest in this context due to its integral role in integrating the HIV genome into that of the infected host cell. Most IN-based antiviral compounds target the IN/DNA interaction, but since IN must first enter the nucleus before it can perform these critical functions, nuclear transport of IN is also an attractive target for therapeutic intervention. Here the authors describe a novel high-throughput screening assay for identifying inhibitors of nuclear import, particularly IN, based on amplified luminescent proximity homogeneous assay (AlphaScreen®) technology, which is high throughput, requires low amounts of material, and is efficient and cost-effective. The authors use the assay to screen for specific inhibitors of the interaction between IN and its nuclear transport receptor importin α/β, successfully identifying several inhibitors of the IN/importin α/β interaction. Importantly, they demonstrate that one of the identified compounds, mifepristone, is effective in preventing active nuclear transport of IN in transfected cells and hence may represent a useful anti-HIV therapeutic. The screen also identified broad-spectrum importin α/β inhibitors such as ivermectin, which may represent useful tools for nuclear transport research in the future. The authors validate the activity and specificity of mifepristone and ivermectin in inhibiting nuclear protein import in living cells, underlining the utility of the screening approach.

1 December 2013 in Antiviral Research
Verified
Journal Article
Closed access
LLLindsay Lundberg
Lindsay Lundberg
CPChelsea Pinkham
Chelsea Pinkham
ABAlan Baer
Alan Baer
MAMoushimi Amaya
Moushimi Amaya
ANAarthi Narayanan
Aarthi Narayanan
KKKylene Kehn-Hall
Kylene Kehn-Hall